QualityStocks would like to highlight
NutraNomics, Inc. (
OTCQB: NNRX), focused on the research and development of nutritional dietary supplements, skin and body care products, and transdermal patches. In addition to creating formulas for hundreds of companies, the company has produced and branded its own product lines which are sold through retail and wholesale channels. Additionally the company private labels and does custom manufacturing for several supplement companies in national and international markets.
In the company’s news,
The nutraceutical industry is expected to reach $75.3 billion in 2017 and grow at a CAGR of nearly 6% between 2013-2017, according to Research and Markets. Dietary supplements are the dominate driver of the industry, gobbling up 37% of market share, followed by functional food and functional beverage segments. Increasing consumer awareness and pursuit of a balanced diet and proper health not only fuels demand for nutraceutical products, but also serves as a catalyst for new product developments.
Since its founding in 1995, Nutranomics’ focus has centered on the research and development of plant-based nutritional dietary supplements, skin and body care products, and transdermal patches. The company rolled out its first product line in 1997, and in addition to continual progression of its own formulas, also private labels and provides custom manufacturing for several supplement companies in national and international markets.
Nutranomics CEO and founder Dr. Tracy K. Gibbs and his experienced management team are preparing to kick-off a marketing plan to increase brand visibility and capture its share of the burgeoning nutraceutical market.
Over the past 18 years, Nutranomics has built an industry reputation of offering superior food and plant-based products blended from the highest quality sources. To ensure this caliber of product, the company employs its own Quality Team that chooses and approves the raw materials and suppliers used in the manufacture of its products. Each batch of materials undergoes a stringent testing process to verify purity, potency and quality. All of the company’s facilities are cGMP compliant in FDA-approved.
Because Nutranomics sells internationally, the company’s products must also meet the higher quality of standards of other countries, such as Japan, where the company achieved triple-digit sales growth in the first quarter of 2014, compared to the prior quarter.
Using its increasing brand awareness and first-quarter performance as momentum, Nutranomics and its new sales team are trained and gearing up to execute the company’s 2014 global expansion goals.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
